Dr Abhilasha Narayan – Consultant Gynae-oncology, robotic and laparoscopic surgery, HCG Cancer Hospital, Bangalore
In India, women often brush off symptoms like bloating and pelvic discomfort, assuming they are caused by common issues like indigestion or menstrual changes. This can result in a delayed diagnosis of ovarian cancer, a disease that is subtle in nature and potentially dangerous. Families and caregivers must be vigilant and listen closely to subtle symptoms, as early detection is crucial. The slow progression of the disease makes it hard to detect, and it’s often advanced by the time it is diagnosed.
Why it is called “silent”
Ovarian cancer rarely produces a clear and an early alarm. Common symptoms like bloating, pelvic pain, feeling loss of appetite or frequent urination are non-specific and can be attributed to everyday conditions. These complaints are so common and vague that the diagnosis is frequently delayed until the disease has progressed. Indian clinical guidance and patient resources emphasises this very challenge as vague and persistent symptom should prompt evaluation rather than reassurance.
Who is at risk — what families should know?
Certain factors raise a woman’s risk with the increasing age, inherited mutations, a strong family history of breast or ovarian cancer, infertility or conditions such as endometriosis, and reproductive history features like nulliparity. Lifestyle and reproductive trends among younger generations are being examined, but genetics and reproductive factors remain the most consistent signals clinicians use when assessing risk. For families with a strong cancer history, specialist genetic counselling and targeted follow-up is recommended.
The limits of screening — why “check-ups” are not simple
Unlike cervical cancer, there is no proven, population-wide screening test for ovarian cancer. Tools such as the CA-125 blood test and pelvic ultrasound are useful in clinical assessment but are not reliably sensitive or specific when used alone for screening asymptomatic women. Indian gynaecologic guidance recommends focused surveillance for high-risk women rather than broad population screening; research continues into better biomarkers and algorithms. This limitation is one reason why awareness of persistent symptoms is vital.
Diagnosis, treatment and outcomes — the Indian context
When symptoms or investigations raise concern, diagnosis is confirmed through imaging and surgical assessment, often followed by histopathology. Treatment typically combines surgery and chemotherapy tailored to the stage and tumour type. Indian cancer centres publish accessible patient guides that explain the stepwise journey from diagnosis to follow-up, stressing multidisciplinary care and support systems for recovery and rehabilitation. Early detection, where achievable, makes a meaningful difference to outcomes, which is why earlier presentation matters.
The burden is changing — what recent data show
Regional reports and registry analyses indicate that the cancer burden across states is evolving, with ovarian cancer remaining a significant contributor to women’s cancer care needs. Government and registry data presented in recent state-level briefings have highlighted the continuing impact of ovarian cancer alongside breast and cervical cancers, reinforcing the need for state and district-level readiness to diagnose and treat these conditions.
What caregivers and women can do today?
-
Listen and act — if bloating, pelvic pain, early satiety, or urinary urgency are new and persist for more than a few weeks, encourage a gynaecological review.
-
Know your family history — share details about breast or ovarian cancers in relatives with clinicians; this can change the recommended approach.
-
Seek specialist advice for high risk — women with a strong family history or known genetic mutations should be offered genetic counselling and tailored surveillance.
-
Support through treatment — practical help with appointments, nutrition, and emotional support improves adherence to therapy and recovery.
Ovarian cancers stealth makes it frightening, but it is not untouchable. When families treat persistent, unexplained symptoms as legitimate reasons to consult, and when high-risk women receive targeted surveillance, instances of late diagnosis can fall. The message for everyone is simple: take persistent symptoms seriously, know your family story, and seek timely evaluation. That vigilance is the clearest defence against a disease that would otherwise remain silent.
